Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
198.77M | 192.64M | 254.38M | 268.68M | 248.17M | Gross Profit |
198.77M | 177.84M | 230.10M | 243.05M | 224.80M | EBIT |
-40.66M | -13.95M | 6.33M | 42.16M | 27.24M | EBITDA |
-40.66M | -10.94M | 9.06M | 45.01M | 30.10M | Net Income Common Stockholders |
-18.90M | 2.51M | 6.28M | 33.15M | 23.34M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
374.64M | 388.26M | 466.86M | 432.81M | 367.74M | Total Assets |
656.20M | 648.44M | 634.25M | 593.79M | 533.46M | Total Debt |
12.36M | 9.40M | 11.14M | 10.05M | 13.61M | Net Debt |
-89.96M | -126.42M | -123.89M | -42.02M | -47.42M | Total Liabilities |
117.66M | 103.53M | 107.05M | 88.86M | 80.19M | Stockholders Equity |
538.55M | 544.91M | 527.20M | 504.93M | 453.27M |
Cash Flow | Free Cash Flow | |||
-16.25M | 12.42M | 31.30M | 63.66M | 49.98M | Operating Cash Flow |
-15.76M | 12.80M | 31.98M | 64.21M | 51.77M | Investing Cash Flow |
-17.43M | -12.06M | 49.92M | -76.70M | -41.50M | Financing Cash Flow |
-155.00K | 0.00 | 734.00K | 3.55M | 5.63M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $2.92B | 12.87 | 38.89% | ― | 31.85% | ― | |
69 Neutral | $13.96B | ― | -8.58% | ― | 46.62% | 50.50% | |
68 Neutral | $11.04B | 33.65 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $1.74B | 23.71 | 7.55% | ― | 8.94% | 5171.26% | |
58 Neutral | $290.41M | ― | -3.49% | ― | 3.18% | -835.29% | |
51 Neutral | $5.94B | ― | -231.63% | ― | 42.53% | -15.29% | |
49 Neutral | $6.86B | 0.03 | -54.79% | 2.48% | 24.62% | -2.84% |
On February 18, 2025, Vanda Pharmaceuticals Inc. announced that its Compensation Committee had awarded 2024 annual bonuses and approved 2025 annual base salaries and bonus target amounts for its executive officers. The committee also granted restricted stock unit awards under the company’s equity incentive plan, with vesting beginning in 2026. This decision follows a review of executive compensation by a consultancy firm and impacts key company stakeholders by setting financial incentives and aligning executive interests with long-term company goals.
On January 25, 2025, Vanda Pharmaceuticals Inc. announced on the social media platform X the filing of a new drug application for tradipitant, intended for treating motion sickness. The announcement highlights the drug’s potential significance, drawing historical parallels to the seasickness challenges faced during WWII and suggesting the condition’s broader impact beyond daily discomfort, potentially affecting national security.